| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Forest Laboratories and its subsidiaries develop, manufacture and market
branded and generic forms of prescription and non-prescription pharmaceutical
products, primarily in the US and Europe. This report provides a full review
of the company's activities together with sales forecasts for key products to
2011.
Forest Laboratories and its subsidiaries develop, manufacture and market
branded and generic forms of prescription and non-prescription pharmaceutical
products, primarily in the US and Europe. Its major products include Namenda
for the treatment of moderate-to-severe Alzheimer's disease, Lexapro for
depression and generalised anxiety disorder, Benicar for hypertension and
Campral for the maintenance of abstinence from alcohol in patients who are
abstinent at treatment initiation.
Since Forest is not able to afford the cost and risk of discovering and
developing its own novel molecules, its business model involves acquiring
products from other companies, at any stage from conception to approval.
On 11th January 2007, Forest successfully completed the acquisition of Cerexa,
a privately-held biopharmaceutical company based in Alameda, CA, in a
cash-for-stock transaction with a purchase price of US$493.6 million plus a
potential US$100 million milestone payment. As a result of the acquisition,
Forest has obtained worldwide development and marketing rights (excluding
Japan) to two injectable antibiotics (ceftaroline and ME1036) and an option to
a third.
To enhance its early-stage pipeline, Forest has entered into a second new
collaboration with Gedeon Richter which will focus on a group of novel
compounds that target the group 1 metabotropic glutamate receptors (mGluR1/5).
mGluR1/5 antagonists represent novel, potential agents for the treatment of
anxiety, depression, pain and other CNS conditions. The companies intend to
advance promising leads to clinical trials within the next two to three years.
In addition, with the acquisition of Cerexa, Forest has acquired ME1036, a
carbapenem antibiotic in preclinical development.
TABLE OF CONTENTS
EXECUTIVE SUMMARY
- Introduction
- Current Financial Position
- Company Performance
- Business Segment Performance
- Geographic Segment Performance
- Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Manufacturing/R&D Infrastructure
- Products/R&D
- Employees
- Product Performance Forecasts
- Pipeline Analysis
- Discontinued R&D Projects
- Conclusions/Outlook
THERAPEUTIC AREA FOCUS
R&D PIPELINE
CENTRAL NERVOUS SYSTEM
- Marketed Products
- Campral
- Celexa
- Combunox
- Lexapro
- Namenda
- Others
- R&D Projects
- mGLUR1/5 antagonists
- Milnacipran
- Neramexane
- RGH-188
- RGH-896
- Growth Forecast
CARDIOVASCULAR
- Marketed Products
- R&D Projects
- Growth Forecast
OTHER
- Marketed Products
- Aerobid
- Armour Thyroid
- Cervidil
- Colomycin
- Infasurf
- Levothroid
- Thyrolar
- R&D Projects
- Aclidinium
- Ceftaroline
- ME1036
- Oglemilast
- Growth Forecast
APPENDIX 1 - FINANCIA L PER FOR MANCE
APPENDIX 2 - KEY COR PORATE EVENTS
APPENDIX 3 - KEY AGRE MENTS
- Almirall Prodesfarma SA
- Aurigene Discovery Technologies Ltd
- BTG Ltd
- Cypress Bioscience Inc
- Daiichi Sankyo
- Gedeon Richter Ltd
- Glenmark Pharmaceuticals Ltd
- INO Therapeutics
- Lundbeck
- Merck KGaA
- Merz Pharma GmbH & Co KGaA
- Mylan Laboratories Inc
- PAION AG
- Recordati
- Procter & Gamble
- Samaritan Pharmaceuticals Inc
APPENDIX 4 - INFRASTR UCTURE
- Research and Development Facilities
- Manufacturing Facilities
APPENDIX 5 - KEY PHAR MACEUTI CAL
APPENDIX 6 - PRO DUCT INDEX
Index of Tables
- Principal Operating Results
- Sales Breakdown
- Long-Lived Assets
- Major Products, Therapeutic Areas And Sales
- Major Central Nervous System Products, 2006
Index of Charts
- Top Selling Products, 2006
- Campral Sales (2001A-2011E)
- Lexapro Sales (2001A-2011E)
- Namenda Sales (2001-2011E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
|
